Protalix BioTherapeutics, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Protalix BioTherapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-12-31 was $0.00.
- Protalix BioTherapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-09-30 was $0.00.
- Protalix BioTherapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-06-30 was $7.78M.
- Protalix BioTherapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-12-31 was $78.00K, a 99.21% decline year-over-year.
- Protalix BioTherapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $7.78M.
- Protalix BioTherapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2018 was $1.37M, a 92.66% decline from fiscal 2017.
- Protalix BioTherapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2017 was $18.65M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $7.78M 10-K · filed 2026-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-06-30 | $7.78M 10-Q · filed 2024-08-14 | |
| 2018-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $1.37M 10-K · filed 2021-03-30 |
| 2018-09-30 | $99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $11.16M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $15.71M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $1.19M 10-Q · filed 2019-05-06 | $19.33M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $18.65M 10-K · filed 2020-03-12 |
| 2017-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-03-18 | |
| 2017-06-30 | $3.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-03-18 | |
| 2017-03-31 | $517.00K 10-Q · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |